BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
58.30
+1.44 (2.53%)
Aug 13, 2025, 4:00 PM - Market closed
BioMarin Pharmaceutical Revenue
BioMarin Pharmaceutical had revenue of $825.41M in the quarter ending June 30, 2025, with 15.92% growth. This brings the company's revenue in the last twelve months to $3.06B, up 18.36% year-over-year. In the year 2024, BioMarin Pharmaceutical had annual revenue of $2.85B with 17.97% growth.
Revenue (ttm)
$3.06B
Revenue Growth
+18.36%
P/S Ratio
3.63
Revenue / Employee
$1,007,766
Employees
3,040
Market Cap
11.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.85B | 434.69M | 17.97% |
| Dec 31, 2023 | 2.42B | 323.19M | 15.42% |
| Dec 31, 2022 | 2.10B | 249.76M | 13.53% |
| Dec 31, 2021 | 1.85B | -14.18M | -0.76% |
| Dec 31, 2020 | 1.86B | 156.41M | 9.18% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
BMRN News
- 8 days ago - BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401 - Seeking Alpha
- 8 days ago - BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030 - Benzinga
- 9 days ago - BioMarin Pharmaceutical Inc. (BMRN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS - PRNewsWire
- 12 days ago - BioMarin Announces Appointment of Ian T. Clark to Board of Directors - PRNewsWire
- 22 days ago - BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET - PRNewsWire
- 6 weeks ago - BioMarin Announces Completion of Acquisition of Inozyme - PRNewsWire
- 7 weeks ago - BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress - PRNewsWire